Back to search results

Observational Study of B-Cell Lymphomas

This study is looking at the natural history of several types of B-cell lymphomas, including Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL). Researchers want to understand how these diseases progress both before and after treatment. By collecting blood, tissue (like bone marrow and lymph node biopsies), and imaging studies (PET and CT scans), they hope to learn more about the molecular changes that happen in these conditions. This information could help identify new targets for future treatments. You may be able to join if you are 18 or older and have one of these diagnoses, whether you are on treatment, have been treated, or are nearing first-line treatment.

Study design
This is an observational study, meaning no specific treatments are being tested. It aims to enroll 1000 participants.
What's involved
The study involves collecting blood, tissue (bone marrow and lymph node biopsies), and/or imaging studies (PET and CT scans). The duration of participation is not specified.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is to study the natural history of MBL/CLL/SLL in patients prior to when their disease needs treatment, with measurements ongoing.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00923507

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Recruiting
Not specifiedAges 18+Observational
National Heart, Lung, and Blood Institute (NHLBI)
~1,000 participants
Updated 2026-08-27 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Study the natural history of MBL/CLL/SLL in patients prior to the time when their disease requires treatment.
Measured over Ongoing

Conditions

Waldenstrom Macroglobulinemia
Lymphoplasmacytic Lymphoma
Monoclonal B-Cell Lymphocytosis
Small Lymphocytic Lymphoma
CLL (Chronic Lymphocytic Leukemia)

Explore related trials

Chronic Lymphocytic LeukemiaLymphoplasmacytic LymphomaSmall Lymphocytic LymphomaWaldenstrom Macroglobulinemia

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Adrian U Wiestner, M.D. · PRINCIPAL_INVESTIGATOR · National Heart, Lung, and Blood Institute (NHLBI)

Who to contact

Ingrid C Frey
[email protected]
(301) 402-0797
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

on treatment or previously treated
requiring or nearing first-line treatment

What this trial measures

  • Study the natural history of MBL/CLL/SLL in patients prior to the time when their disease requires treatment.Ongoing

    Treatment free survival, measured as the time from diagnosis or last therapy to the development of active disease that requires treatment at which time patients will be able to change to a treatment protocol or seek treatment outside of NIH.